Outcomes of allogeneic haematopoietic stem cell transplantation for patients with severe aplastic anaemia using the porcine antilymphocyte globulin-containing conditioning regimen

被引:5
|
作者
Li, Lin [1 ]
Li, Yun [1 ]
Lin, Li [1 ]
Yin, Jin [1 ]
Xu, Jinhuan [1 ]
Wei, Jia [1 ]
Zhang, Yicheng [1 ,2 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Hematol, 1095 Jie Fang Ave, Wuhan 430030, Hubei, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Inst Organ Transplantat, Wuhan 430030, Peoples R China
基金
中国国家自然科学基金;
关键词
Porcine antilymphocyte globulin; Allogeneic haematopoietic stem cell transplantation; Severe aplastic anaemia; Conditioning regimen; VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; TERM-FOLLOW-UP; HUMAN THYMOCYTE IMMUNOGLOBULIN; RABBIT ANTITHYMOCYTE GLOBULIN; INVASIVE FUNGAL DISEASE; POOR GRAFT FUNCTION; CYCLOSPORINE-A; PREPARATIVE REGIMEN; COOPERATIVE GROUP;
D O I
10.1007/s00277-020-04111-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Antithymocyte globulin (ATG) is widely used for allogeneic haematopoietic stem cell transplantation (allo-HSCT) in severe aplastic anaemia (SAA). Only rabbit-ATG (r-ATG) and porcine-antilymphocyte globulin (p-ALG) are available in China, but the p-ALG-containing conditioning regimen for allo-HSCT in SAA has seldom been reported. In this study, we retrospectively evaluated the outcomes of 41 SAA patients receiving allo-HSCT with a p-ALG-containing conditioning regimen in our transplantation centre. All patients engrafted, and no death during conditioning was observed. The actuarial 3-year overall survival (OS) rates were 95.1 +/- 3.4%. The actuarial 3-year disease-free survival (DFS) rates were 85.0 +/- 5.7%. Acute graft-versus-host disease (aGVHD)predicted inferior OS (p < 0.05). The interval from diagnosis to transplantation for more than 100 days predicted an inferior DFS rate (p < 0.05) and a higher graft rejection/poor graft function (GR/PGF) rate (p < 0.01). In conclusion, the p-ALG-containing regimen showed satisfactory effects and safety in allo-HSCT for SAA patients. P-ALG could be a potential alternative preparation for r-ATG in SAA allo-HSCT.
引用
收藏
页码:1863 / 1871
页数:9
相关论文
共 50 条
  • [31] Clinical and genetic profiles and outcomes of allogeneic haematopoietic stem cell transplantation in secondary myelodysplastic syndrome following aplastic anaemia
    Li, Jia
    Ma, Runzhi
    Wang, Hui
    Wang, Yan
    Pang, Aiming
    Yang, Donglin
    Chen, Xin
    Zhang, Rongli
    Wei, Jialin
    Ma, Qiaoling
    Zhai, Weihua
    He, Yi
    Zheng, Yizhou
    Jiang, Erlie
    Han, Mingzhe
    Feng, Sizhou
    BRITISH JOURNAL OF HAEMATOLOGY, 2025, 206 (02) : 753 - 757
  • [32] Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up
    Kahl, C
    Leisenring, W
    Deeg, HJ
    Chauncey, TR
    Flowers, MED
    Martin, PJ
    Sanders, JE
    Storb, R
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 130 (05) : 747 - 751
  • [33] Unrelated donor stem cell transplantation in severe aplastic anaemia using a fludarabine and thymoglobulin-based reduced intensity conditioning regimen
    Alho, A.
    Espada, E.
    Sousa, P. S.
    Martins, C.
    Lourenco, F.
    Moreno, R.
    Rodrigues, A.
    Juncal, C.
    Garcao, A.
    Ferrao, A.
    Palare, M.
    Morais, A.
    Lacerda, J.
    do Carmo, J. A.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S414 - S414
  • [34] Allogeneic haematopoietic stem cell transplantation in paediatric patients with Fanconi's anemia and severe aplastic anemia
    Hamidieh, A.
    Behfar, M.
    Alimoghaddam, K.
    Jahani, M.
    Bahar, B.
    Mousavi, S. A.
    Iravani, M.
    Ostadali, M. R.
    Jalali, A.
    Hamdi, A.
    Jalili, M.
    Basirpanah, S.
    Hosseini, A.
    Sharifi, L.
    Ghavamzadeh, A.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S220 - S220
  • [35] Second allogeneic haematopoietic stem cell transplantation using reduced-intensity conditioning regimen as treatment for haematological malignancies relapsing following first allogeneic haematopoietic stem cell transplantation
    Katayama, Y.
    Iwato, K.
    Toishigawa, K.
    Ochi, T.
    Okatani, T.
    Imanaka, R.
    Kyo, K.
    Itagaki, M.
    Asaoku, H.
    Kyo, T.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S435 - S435
  • [36] Clinical relevance of serial quantitative analysis of haematopoietic chimerism after allogeneic stem cell transplantation in children for severe aplastic anaemia
    Bader, P
    Hoelle, W
    Kreyenberg, H
    Lang, P
    Gruhn, B
    Führer, M
    Niethammer, D
    Klingebiel, T
    Beck, JF
    BONE MARROW TRANSPLANTATION, 2004, 33 : S63 - S63
  • [37] A single centre experience with allogeneic stem cell transplantation for severe aplastic anaemia in childhood
    Ladenstein, R
    Peters, C
    Minkov, M
    EmmingerSchmidmeier, W
    Mann, G
    Hocker, P
    Hawliczek, R
    Rosenmayr, A
    Fink, FM
    Niederwieser, D
    Gadner, H
    KLINISCHE PADIATRIE, 1997, 209 (04): : 201 - 208
  • [38] Non-myeloablative haematopoietic stem cell transplantation for severe aplastic anaemia with various complications
    Murotani, Y
    Kuroda, J
    Kimura, S
    Terao, K
    Fukiya, E
    Ozawa, M
    Kobayashi, Y
    Yoshikawa, T
    CLINICAL AND LABORATORY HAEMATOLOGY, 2002, 24 (05): : 303 - 306
  • [39] Allogeneic Hematopoietic Cell Transplantation for Severe Epidermolysis Bullosa: Impact of Conditioning Regimen and Stem Cell Source On Outcomes
    Tolar, Jakub
    McGrath, John A.
    Osborn, Mark J.
    Hook, Kristen P.
    Keene, Douglas R.
    Hordinsky, Maria K.
    Blazar, Bruce R.
    Wagner, John E.
    BLOOD, 2012, 120 (21)
  • [40] Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with sickle-cell disease
    Zecca, M.
    Lisini, D.
    Leoni, M. C.
    Bernardo, M. E.
    Mastronuzzi, A.
    Guerini, P.
    Ottonello, G.
    Zavras, N.
    Bonetti, F.
    Giorgiani, G.
    Locatelli, F.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S35 - S35